Outstanding Care, Compassionate People, Healthier Communities

NHS Sherwood Forest Hospitals NHS Foundation Trust

King's Mill Hospital
Mansfield Road
Sutton in Ashfield
Nottinghamshire
NG17 4JL

Tel: 01623 622515
Join today: www.sfh-tr.nhs.uk

King's Mill Hospital
Mansfield Road
Sutton in Ashfield
Nottinghamshire
NG17 4JL

Tel: 01623 622515
Join today: www.sfh-tr.nhs.uk

Direct Line: 01623 672232
Our Ref: 1210
E-mail: sfh-tr.foi.requests@nhs.net

5th December 2025

[redacted]

Dear Sir/Madam

Freedom of Information Act (FOI) 2000 - Request for Information Reference: FOI Request: Treatment of breast cancer

I am writing in response to your request for information under the FOI 2000.

I can confirm in accordance with Section 1 (1) of the Freedom of Information Act 2000 that we do hold the information you have requested. A response to each part of your request is provided below.

FOI Request / Question	Question Response	Is there an exemption?	Exemption	Exemption Details
1. How many patients were treated in total, regardless of diagnosis, with the following medicines in the 3 months between the start of 1st July 2025 to the end of September 2025? • Abemaciclib (Verzenios) • Alpelisib (Piqray) • Elacestrant (Orserdu) • Fulvestrant (fulvestrant or Faslodex) • Inavolisib (Inaqovi) • Palbociclib (Ibrance) • Ribociclib (Kisqali) • Capivasertib (Truqap) • Talazoparib (Talzenna) • Olaparib (Lynparza)	• Abemaciclib (Verzenios) – 5 Patients • Alpelisib (Piqray) – 0 Patients • Elacestrant (Orserdu) – 0 Patients • Fulvestrant (fulvestrant or Faslodex) – 10 Patients • Inavolisib (Inaqovi) – 0 Patients • Palbociclib (Ibrance) – 0 Patients • Ribociclib (Kisqali) – 0 Patients • Capivasertib (Truqap) – 0 Patients • Talazoparib (Talzenna) – 0 Patients • Olaparib (Lynparza) – 1 Patients			
2. How many patients received the following medicines for early breast cancer in the 3 months between 1st July 2025 to the end of September 2025? • Abemaciclib (Verzenios) • Ribociclib (Kisqali) • Olaparib (Lynparza)	• Abemaciclib (Verzenios) – 1 Patients • Ribociclib (Kisqali) – 0 Patients • Olaparib (Lynparza) – Patients			

Patient Experience Team
01623 672222
sfh-tr.pet@nhs.net

3. How many patients received the following medicines with curative treatment intent in the 3 months between 1st July 2025 to the end of September 2025? • Abemaciclib (Verzenios) • Ribociclib (Kisqali)	• Abemaciclib (Verzenios) – 1 Patients • Ribociclib (Kisqali) – 0 Patients			
4. How many patients were treated with the following medicines in combination with fulvestrant in the 3 months between the 1st July 2025 to the end of September 2025? • Abemaciclib (Verzenios) + Fulvestrant (fulvestrant or Faslodex) • Palbociclib (Ibrance) + Fulvestrant (fulvestrant or Faslodex) • Ribociclib (Kisqali) + Fulvestrant (fulvestrant or Faslodex)	• Abemaciclib (Verzenios) + Fulvestrant (fulvestrant or Faslodex) • Palbociclib (Ibrance) + Fulvestrant (fulvestrant or Faslodex • Ribociclib (Kisqali) + Fulvestrant (fulvestrant or Faslodex) Information not held in the requested format to identify drugs in combination.			
5. How many patients were treated with Olaparib (Lynparza) for the following types of breast cancer in the 3 months between the 1st July 2025 to the end of September 2025? • All types of breast cancer • Locally advanced or metastatic breast cancer	• All types of breast cancer – 1 Patient • Locally advanced or metastatic breast cancer – 0 Patients			
6. How many patients were treated in total with the following products in the 3 months between	• Pertuzumab (Perjeta) – 0 Patients • Pertuzumab with Trastuzumab (Phesgo) – 0			

Patient Experience Team
01623 672222
sfh-tr.pet@nhs.net

1st July 2025 to the end of September 2025? • Pertuzumab (Perjeta) • Pertuzumab with Trastuzumab (Phesgo) • Trastuzumab (Herceptin, Herzuma, Kanjinti, Ontruzant, Trazimera, Zercepac, trastuzumab) • Trastuzumab Deruxtecan (EnHertu) • Trastuzumab Emtansine (Kadcyla) • Tucatinib (Tukysa) • Neratinib (Nerlynx)	Patients • Trastuzumab (Herceptin, Herzuma, Kanjinti, Ontruzant, Trazimera, Zercepac, trastuzumab) – 0 Patients • Trastuzumab Deruxtecan (EnHertu) – 0 Patients • Trastuzumab Emtansine (Kadcyla) – 0 Patients • Tucatinib (Tukysa) – 0 Patients • Neratinib (Nerlynx) – 0 Patients			
7. How many patients were treated with the following products for a diagnosis of Breast Cancer (ICD-10 codes = C50*, D509) in the 3 months between 1st July 2025 to the end of September 2025? • Trastuzumab (Herceptin, Herzuma, Kanjinti, Ontruzant, Trazimera, Zercepac, trastuzumab) • Trastuzumab Deruxtecan (EnHertu)	• Trastuzumab (Herceptin, Herzuma, Kanjinti, Ontruzant, Trazimera, Zercepac, trastuzumab) – 0 Patients • Trastuzumab Deruxtecan (EnHertu) – 0 Patients			
8. How many patients received the following products with curative treatment intent in the 3 months between the 1st July 2025 to the end of September 2025? • Pertuzumab (Perjeta) • Pertuzumab with Trastuzumab (Phesgo) • Trastuzumab (Herceptin, Herzuma, Kanjinti,	• Pertuzumab (Perjeta) – 0 Patients • Pertuzumab with Trastuzumab (Phesgo) – 0 Patients • Trastuzumab (Herceptin, Herzuma, Kanjinti, Ontruzant, Trazimera, Zercepac, Trastuzumab) – 0 Patients • Trastuzumab Emtansine (Kadcyla) – 0 Patients			

Patient Experience Team
01623 672222
sfh-tr.pet@nhs.net

Ontruzant, Trazimera, Zercepac, Trastuzumab) • Trastuzumab Emtansine (Kadcyla)				
9. How many patients received the following products as part of neoadjuvant or adjuvant therapy in the 3 months between the 1st July 2025 to the end of September 2025? • Pertuzumab (Perjeta) • Pertuzumab with Trastuzumab (Phesgo) • Trastuzumab (Herceptin, Herzuma, Kanjinti, Ontruzant, Trazimera, Zercepac, trastuzumab) • Trastuzumab Emtansine (Kadcyla)	• Pertuzumab (Perjeta) – 0 Patients • Pertuzumab with Trastuzumab (Phesgo) – 0 Patients • Trastuzumab (Herceptin, Herzuma, Kanjinti, Ontruzant, Trazimera, Zercepac, trastuzumab) – 0 Patients • Trastuzumab Emtansine (Kadcyla) – 0 Patients			
10. How many patients received trastuzumab deruxtecan (Enhertu) for the following types of breast cancer in the 3 months between the 1st July 2025 to the end of September 2025? • HER2+ve Breast Cancer • HER2-low Breast Cancer	• HER2+ve Breast Cancer – 0 Patients • HER2-low Breast Cancer – 0 Patients			

Patient Experience Team
01623 672222
sfh-tr.pet@nhs.net

11. How many patients were treated for the following indications for metastatic HER2+ve breast cancer by product, in the 3 months between 1st July 2025 and 30th September 2025, or latest 3-months for which data are available? a) Following one prior anti HER2-based regimen • Trastuzumab Deruxtecan (Enhertu) • Trastuzumab Emtansine (Kadcyla) • Trastuzumab b) Following one or more prior anti-HER2-based regimens • Trastuzumab Deruxtecan (Enhertu) • Trastuzumab Emtansine (Kadcyla) • Trastuzumab	• Trastuzumab Deruxtecan (Enhertu) – 0 Patients • Trastuzumab Emtansine (Kadcyla) – 0 Patients • Trastuzumab b) Following one or more prior anti-HER2-based regimens – 0 Patients • Trastuzumab Deruxtecan (Enhertu) – 0 Patients • Trastuzumab Emtansine (Kadcyla) – 0 Patients • Trastuzumab – 0 Patients			

Patient Experience Team
01623 672222
sfh-tr.pet@nhs.net

I trust this information answers your request. Should you have any further enquiries or queries about this response please do not hesitate to contact me. However, if you are unhappy with the way in which your request has been handled, you have the right to ask for an internal review. Internal review requests should be submitted within two months of the date of receipt of the response to your original letter and should be addressed to: Sally Brook Shanahan, Director of Corporate Affairs, King's Mill Hospital, Mansfield Road, Sutton in Ashfield, Nottinghamshire, NG17 4JL or email sally.brookshanahan@nhs.net.

If you are dissatisfied with the outcome of the internal review, you can apply to the Information Commissioner's Office, who will consider whether we have complied with our obligations under the Act and can require us to remedy any problems. Generally, the Information Commissioner's Office cannot decide unless you have exhausted the internal review procedure. You can find out more about how to do this, and about the Act in general, on the Information Commissioner's Office website at: https://ico.org.uk/your-data-matters/official-information/.

Complaints to the Information Commissioner's Office should be sent to FOI/EIR Complaints Resolution, Information Commissioner's Office, Wycliffe House, Water Lane, Wilmslow, Cheshire, SK9 5AF. Telephone 0303 1231113, email casework@ico.org.uk.

If you would like this letter or information in an alternative format, for example large print or easy read, or if you need help with communicating with us, for example because you use British Sign Language, please let us know. You can call us on 01623 672232 or email sfh-tr.foi.requests@nhs.net.

Yours faithfully

Information Governance Team

All information we have provided is subject to the provisions of the Re-use of Public Sector Information Regulations 2015. Accordingly, if the information has been made available for re-use under the Open Government Licence (OGL) a request to re-use is not required, but the licence conditions must be met. You must not re-use any previously unreleased information without having the consent from Sherwood Forest Hospitals NHS Foundation Trust. Should you wish to re-use previously unreleased information then you must make your request in writing. All requests for re-use will be responded to within 20 working days of receipt.

Patient Experience Team
01623 672222
sfh-tr.pet@nhs.net